UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant þ | Filed by a Party other than the Registrant ¨ | |||||||||||||||||||
| Check the appropriate box: | ||||||||||||||||||||
| ¨ | Preliminary Proxy Statement | |||||||||||||||||||
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |||||||||||||||||||
| ¨ | Definitive Proxy Statement | |||||||||||||||||||
| þ | Definitive Additional Materials | |||||||||||||||||||
| ¨ | Soliciting Material under §240.14a-12 | |||||||||||||||||||
XERIS BIOPHARMA HOLDINGS, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |||||||||||||||||||||||
| þ | No fee required. | ||||||||||||||||||||||
| ¨ | Fee previously paid with preliminary materials. | ||||||||||||||||||||||
| ¨ | Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11. | ||||||||||||||||||||||
